Latest News and Press Releases

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.

CALGARY, Alberta, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (the “Company” or “Black Diamond”) (TSX:BDI, OTCQX:BDIMF) is pleased to announce the renewal and expansion of its...

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....

Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.

ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed...

WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...

ALACHUA, Fla. and TAMPA, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...